PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway
IntroductionIn thyroid carcinoma (TC), follicular thyroid carcinoma (FTC) represents the second most prevalent pathological type following papillary thyroid carcinoma. Notably, FTC exhibits a more aggressive clinical course and a higher propensity for distant metastasis. However, the underlying mech...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1502391/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582872371822592 |
|---|---|
| author | Haobo Wang Fangjian Shang Yifang Wang Bo Pang Bo Pang Longfei Kang Longfei Kang Chuanmin Zhou Chuanmin Zhou Dongyun Li Dongyun Li Zhongxin Li Zhongxin Li Xia Jiang Xia Jiang Bo Liu Zengren Zhao |
| author_facet | Haobo Wang Fangjian Shang Yifang Wang Bo Pang Bo Pang Longfei Kang Longfei Kang Chuanmin Zhou Chuanmin Zhou Dongyun Li Dongyun Li Zhongxin Li Zhongxin Li Xia Jiang Xia Jiang Bo Liu Zengren Zhao |
| author_sort | Haobo Wang |
| collection | DOAJ |
| description | IntroductionIn thyroid carcinoma (TC), follicular thyroid carcinoma (FTC) represents the second most prevalent pathological type following papillary thyroid carcinoma. Notably, FTC exhibits a more aggressive clinical course and a higher propensity for distant metastasis. However, the underlying mechanisms governing the progression of FTC remain poorly understood. PMAIP1 is a gene implicated in various cancers and biological processes. Investigating the role and mechanism of PMAIP1 in FTC is crucial for enhancing our understanding of FTC and informing clinical treatment strategies. MethodsThis study examined the expression level of PMAIP1 in FTC through comprehensive analysis of databases, tumor tissues, and cell lines. Following the establishment of a stably transfected plasmid in cell lines, a series of functional assays and subcutaneous xenograft experiment were conducted to investigate the role of PMAIP1 in FTC. Additionally, transcriptome sequencing was employed to identify potential signaling pathways associated with PMAIP1. Mechanistic studies involved a series of rescue experiments to elucidate the regulatory mechanisms of PMAIP1 in FTC. ResultsPMAIP1 was found to be highly expressed in FTC, and its knockdown significantly inhibited the proliferation and metastasis of FTC cells both in vivo and in vitro. The results of transcriptome sequencing analysis indicated that PMAIP1 may influence the progression of FTC via the Wnt signaling pathway. Subsequent investigations revealed a direct correlation between PMAIP1 expression levels and those of Wnt3 and FOSL1 in FTC. A series of rescue experiments further substantiated the regulatory role of PMAIP1 on Wnt3/FOSL1 in FTC. DiscussionIn conclusion, our research demonstrated that PMAIP1 emerges as a novel pro-cancer factor in FTC, and its knockdown significantly inhibited the proliferation and metastasis of FTC both in vivo and in vitro. Mechanistically, PMAIP1 regulated FOSL1 by modulating the Wnt signaling pathway, thereby promoting FTC progression. Targeting PMAIP1 may present a promising therapeutic strategy for FTC. |
| format | Article |
| id | doaj-art-7323e15ebb8541409d2a3180b5bce2d9 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-7323e15ebb8541409d2a3180b5bce2d92025-01-29T06:46:11ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.15023911502391PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathwayHaobo Wang0Fangjian Shang1Yifang Wang2Bo Pang3Bo Pang4Longfei Kang5Longfei Kang6Chuanmin Zhou7Chuanmin Zhou8Dongyun Li9Dongyun Li10Zhongxin Li11Zhongxin Li12Xia Jiang13Xia Jiang14Bo Liu15Zengren Zhao16Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaGastrointestinal Disease Diagnosis and Treatment Center, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaGastrointestinal Disease Diagnosis and Treatment Center, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaGastrointestinal Disease Diagnosis and Treatment Center, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaGastrointestinal Disease Diagnosis and Treatment Center, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaGastrointestinal Disease Diagnosis and Treatment Center, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaGastrointestinal Disease Diagnosis and Treatment Center, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, ChinaIntroductionIn thyroid carcinoma (TC), follicular thyroid carcinoma (FTC) represents the second most prevalent pathological type following papillary thyroid carcinoma. Notably, FTC exhibits a more aggressive clinical course and a higher propensity for distant metastasis. However, the underlying mechanisms governing the progression of FTC remain poorly understood. PMAIP1 is a gene implicated in various cancers and biological processes. Investigating the role and mechanism of PMAIP1 in FTC is crucial for enhancing our understanding of FTC and informing clinical treatment strategies. MethodsThis study examined the expression level of PMAIP1 in FTC through comprehensive analysis of databases, tumor tissues, and cell lines. Following the establishment of a stably transfected plasmid in cell lines, a series of functional assays and subcutaneous xenograft experiment were conducted to investigate the role of PMAIP1 in FTC. Additionally, transcriptome sequencing was employed to identify potential signaling pathways associated with PMAIP1. Mechanistic studies involved a series of rescue experiments to elucidate the regulatory mechanisms of PMAIP1 in FTC. ResultsPMAIP1 was found to be highly expressed in FTC, and its knockdown significantly inhibited the proliferation and metastasis of FTC cells both in vivo and in vitro. The results of transcriptome sequencing analysis indicated that PMAIP1 may influence the progression of FTC via the Wnt signaling pathway. Subsequent investigations revealed a direct correlation between PMAIP1 expression levels and those of Wnt3 and FOSL1 in FTC. A series of rescue experiments further substantiated the regulatory role of PMAIP1 on Wnt3/FOSL1 in FTC. DiscussionIn conclusion, our research demonstrated that PMAIP1 emerges as a novel pro-cancer factor in FTC, and its knockdown significantly inhibited the proliferation and metastasis of FTC both in vivo and in vitro. Mechanistically, PMAIP1 regulated FOSL1 by modulating the Wnt signaling pathway, thereby promoting FTC progression. Targeting PMAIP1 may present a promising therapeutic strategy for FTC.https://www.frontiersin.org/articles/10.3389/fonc.2025.1502391/fullfollicular thyroid carcinomaPMAIP1Wnt3FOSL1progression |
| spellingShingle | Haobo Wang Fangjian Shang Yifang Wang Bo Pang Bo Pang Longfei Kang Longfei Kang Chuanmin Zhou Chuanmin Zhou Dongyun Li Dongyun Li Zhongxin Li Zhongxin Li Xia Jiang Xia Jiang Bo Liu Zengren Zhao PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway Frontiers in Oncology follicular thyroid carcinoma PMAIP1 Wnt3 FOSL1 progression |
| title | PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway |
| title_full | PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway |
| title_fullStr | PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway |
| title_full_unstemmed | PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway |
| title_short | PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway |
| title_sort | pmaip1 regulates the progression of follicular thyroid carcinoma through the wnt3 fosl1 pathway |
| topic | follicular thyroid carcinoma PMAIP1 Wnt3 FOSL1 progression |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1502391/full |
| work_keys_str_mv | AT haobowang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT fangjianshang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT yifangwang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT bopang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT bopang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT longfeikang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT longfeikang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT chuanminzhou pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT chuanminzhou pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT dongyunli pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT dongyunli pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT zhongxinli pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT zhongxinli pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT xiajiang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT xiajiang pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT boliu pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway AT zengrenzhao pmaip1regulatestheprogressionoffollicularthyroidcarcinomathroughthewnt3fosl1pathway |